NCI budget: a “Yes” to one thing means a “No” to something else, director says.
Also in this 8-page issue: Bush nominates McClellan to head CMS.
FDA to refer false statements by regulated companies to SEC.
Sandra Horning elected ASCO president-elect.
Medicare coverage and quality of care top ASCO’s list of policy priorities for 2004.
NIH appoints panel to review conflict of interest rules.
Funding opportunities listed.
PDF file includes 8-page February issue of Business & Regulatory Report.
Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - With five-year cancer survival at an all-time high, does this mean people are living longer?
- Blood Cancer United: A new name at the right moment
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - In The Headlines: Is early detection always good? Inside NCI’s MCD feasibility trial.
- Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer
